Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-BTN1A1 monoclonal antibody hSTC810

A humanized monoclonal antibody directed against the immune checkpoint protein butyrophilin 1A1 (BTN1A1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti- BTN1A1 monoclonal antibody hSTC810 targets and binds to the extracellular domain of human BTN1A1, which prevents the formation of the BTN1A1-galectin-9 (Gal9)-programmed cell death protein 1 (PD-1) complex, and inhibits downstream signaling pathways. This may restore immune function through the activation of T cells and T-cell-mediated immune responses against tumor cells. The BTN1A1-Gal9-PD-1 axis suppresses T-cell receptor (TCR) signaling and T-cell activation. BTN1A1 does not bind to PD-1 directly but interacts with PD-1 through Gal9. BTN1A1, a member of the butyrophilin superfamily of immunomodulators, is upregulated in a variety of tumor cell types.
Synonym:anti-butyrophilin 1A1 monoclonal antibody hSTC810
Code name:hSTC 810
hSTC-810
hSTC810
Search NCI's Drug Dictionary